Totrombopag

• Description:

  Totrombopag is an orally effective thrombopoietin receptor (TpoR) agonist. By activating TpoR, Totrombopag initiates an intracellular signaling cascade mediated by JAK2 kinase and the transcription factor Stat5, a signaling process that is the primary mechanism regulating megakaryocyte growth and differentiation into platelets. Totrombopag can be used to study platelet production and megakaryocyte biology[1].

• UNSPSC:

  12352005

• Target:

  Thrombopoietin Receptor

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Others

• Assay Protocol:

  https://www.medchemexpress.com/totrombopag.html

• Concentration:

  10mM

• Purity:

  99.00

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  O=C1N (C2=CC=C (C) C (C) =C2) N=C (C1/N=N/C3=C (O) C (C4=CC (C5=NN=NN5) =CC=C4) =CC=C3) C

• Molecular Formula:

  C25H22N8O2

• Molecular Weight:

  466.49

• References & Citations:

  [1]Alper P B, et al. Discovery and biological evaluation of benzo [a] carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor[J]. Bioorganic & medicinal chemistry letters, 2008, 18 (19) : 5255-5258.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• CAS Number:

  376592-42-6